Page last updated: 2024-12-11

seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide: a proteinase-activated receptor-2-activating peptide; SL-NH2 is NOT Ser-Leu-NH2 here [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9831050
CHEMBL ID238078
MeSH IDM0290594

Synonyms (24)

Synonym
CHEMBL238078 ,
par-2 activation peptide
sligrl-nh2 ,
sl-nh2
seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide
bdbm85517
cas_171436-38-7
171436-38-7
AKOS024456619
bdbm50477070
par-2 (1-6) amide (mouse, rat) trifluoroacetate salt, >=97% (hplc)
h-ser-leu-ile-gly-arg-leu-nh2
CS-0029354
HY-P1308
sligrl (modifications: c-terminal amide)
c29h56n10o7
HB2920
ser-leu-ile-gly-arg-leu-nh(2)
ser-leu-ile-gly-arg-leu-amide
ser-leu-ile-gly-arg-leu-nh2
par-2 activating peptide
(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-n-[2-[[(2s)-1-[[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]-3-methylpentanamide
AS-82543
AKOS040763878
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proteinase-activated receptor 2Homo sapiens (human)EC50 (µMol)5.85000.02512.288310.0000AID301247; AID363236; AID772492; AID772493
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (55)

Processvia Protein(s)Taxonomy
vasodilationProteinase-activated receptor 2Homo sapiens (human)
T cell activation involved in immune responseProteinase-activated receptor 2Homo sapiens (human)
positive regulation of leukocyte chemotaxisProteinase-activated receptor 2Homo sapiens (human)
positive regulation of cytokine production involved in immune responseProteinase-activated receptor 2Homo sapiens (human)
positive regulation of glomerular filtrationProteinase-activated receptor 2Homo sapiens (human)
inflammatory responseProteinase-activated receptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProteinase-activated receptor 2Homo sapiens (human)
blood coagulationProteinase-activated receptor 2Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
regulation of blood coagulationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of cell migrationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of actin filament depolymerizationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of pseudopodium assemblyProteinase-activated receptor 2Homo sapiens (human)
negative regulation of chemokine productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of chemokine productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of type II interferon productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of interleukin-1 beta productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of interleukin-10 productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of interleukin-6 productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of interleukin-8 productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of superoxide anion generationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of toll-like receptor 2 signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
negative regulation of toll-like receptor 3 signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
positive regulation of toll-like receptor 3 signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
positive regulation of toll-like receptor 4 signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
positive regulation of Rho protein signal transductionProteinase-activated receptor 2Homo sapiens (human)
neutrophil activationProteinase-activated receptor 2Homo sapiens (human)
regulation of canonical NF-kappaB signal transductionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of eosinophil degranulationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of GTPase activityProteinase-activated receptor 2Homo sapiens (human)
innate immune responseProteinase-activated receptor 2Homo sapiens (human)
cell-cell junction maintenanceProteinase-activated receptor 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIProteinase-activated receptor 2Homo sapiens (human)
regulation of JNK cascadeProteinase-activated receptor 2Homo sapiens (human)
negative regulation of JNK cascadeProteinase-activated receptor 2Homo sapiens (human)
positive regulation of JNK cascadeProteinase-activated receptor 2Homo sapiens (human)
negative regulation of insulin secretionProteinase-activated receptor 2Homo sapiens (human)
leukocyte migrationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of chemotaxisProteinase-activated receptor 2Homo sapiens (human)
positive regulation of positive chemotaxisProteinase-activated receptor 2Homo sapiens (human)
defense response to virusProteinase-activated receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of phagocytosis, engulfmentProteinase-activated receptor 2Homo sapiens (human)
establishment of endothelial barrierProteinase-activated receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProteinase-activated receptor 2Homo sapiens (human)
thrombin-activated receptor signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
leukocyte proliferationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of neutrophil mediated killing of gram-negative bacteriumProteinase-activated receptor 2Homo sapiens (human)
mature conventional dendritic cell differentiationProteinase-activated receptor 2Homo sapiens (human)
potassium channel activating, G protein-coupled receptor signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
positive regulation of renin secretion into blood streamProteinase-activated receptor 2Homo sapiens (human)
regulation of chemokine (C-X-C motif) ligand 2 productionProteinase-activated receptor 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingProteinase-activated receptor 2Homo sapiens (human)
protease bindingProteinase-activated receptor 2Homo sapiens (human)
G protein-coupled receptor activityProteinase-activated receptor 2Homo sapiens (human)
signaling receptor bindingProteinase-activated receptor 2Homo sapiens (human)
protein bindingProteinase-activated receptor 2Homo sapiens (human)
thrombin-activated receptor activityProteinase-activated receptor 2Homo sapiens (human)
G-protein beta-subunit bindingProteinase-activated receptor 2Homo sapiens (human)
signaling receptor activityProteinase-activated receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
early endosomeProteinase-activated receptor 2Homo sapiens (human)
Golgi apparatusProteinase-activated receptor 2Homo sapiens (human)
plasma membraneProteinase-activated receptor 2Homo sapiens (human)
pseudopodiumProteinase-activated receptor 2Homo sapiens (human)
plasma membraneProteinase-activated receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID175860In vitro vasorelaxant activity in male wistar rat thoracic aorta by classical rat aorta relaxation assay2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Minimal structural requirements for agonist activity of PAR-2 activating peptides.
AID772492Agonist activity at PAR2 (unknown origin) by cell-based assay2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Toward drugs for protease-activated receptor 2 (PAR2).
AID1327845Half life in Wistar rat plasma at 10 uM by LC/MS/MS analysis
AID363237Agonist activity at human PAR2 expressed in HEK293T cells assessed as effect on intracellular calcium mobilization by R-SAT assay relative to SLIGRL-NH22008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of potent and selective small-molecule PAR-2 agonists.
AID772493Agonist activity at PAR2 in human HT-29 cells assessed as increase in intracellular calcium release2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Toward drugs for protease-activated receptor 2 (PAR2).
AID301247Agonist activity at PAR2 expressed in human HT29 cells assessed as intracellular calcium release2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
A refined agonist pharmacophore for protease activated receptor 2.
AID1327838Elimination half life in Wistar rat liver homogenate at 10 uM by LC/MS/MS analysis
AID363236Agonist activity at human PAR2 expressed in HEK293T cells assessed as effect on intracellular calcium mobilization by R-SAT assay2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of potent and selective small-molecule PAR-2 agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (126)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (9.52)18.2507
2000's68 (53.97)29.6817
2010's46 (36.51)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.10 (24.57)
Research Supply Index4.84 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.79%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other125 (99.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]